New York Post
Every cancer patient enters remission after drug trial, study reveals
- - - - - -
被験者数が18人ながら、直腸がんがすべて消滅したという薬剤開発のニュースです。
A recent drug trial administered to a handful of cancer patients had the surprising result of eliminating (消滅させる) the disease in every participant involved.
The study was conducted on 18 rectal cancer (直腸がん) patients at Memorial Sloan Kettering Cancer Center in Manhattan and had a 100 percent success rate, according to a paper published Sunday in the New England Journal of Medicine.
“I believe this is the first time this has happened in the history of cancer,” Dr. Luis A. Diaz Jr, the author of the paper, told the New York Times.
The drug, dostarlimab, was administered (投与する) to each patient every three weeks for six months.
Participants in the study were suffering from rectal cancer and were given alternatives such as chemotherapy or a difficult surgery that could potentially lead to bowel or urinary dysfunction.
Some patients are required to use a colostomy bag (ストーマ装具) due to treatment, the Times said.
At the conclusion of the drug trial, however, the patients were spared (免れる) the agony of potentially damaging treatment when they showed no evidence of a tumor after receiving an MRI, rectal examination and biopsy.
-----
In addition to not needing further treatment to eradicate (根絶する) the disease, there were no instances of a recurrence of cancer (再発) in the patients during follow-up appointments from six to 25 months after the trial ended.
投薬だけで100％の奏効が得られたということです。
これを上のウェブサイトでは "a 100% success rate"
別のウェブサイトでは"a 100% complete response rate among its patients"と言っています。
化学療法も手術も避けられるのですね。
正式な論文発表はこちら
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM